Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant trastuzumab plus docetaxel followed by trastuzumab plus pegylated liposomal doxorubicin and cyclophosphamide in HER2-positive operable or locally advanced breast cancer
2006-003993-85Phase 2Terminated
- Sponsor
- Istituto Nazionale Tumori IRCCS Fondazione Pascale
- Start
- Jun 2007
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab, docetaxel, doxorubicin and cyclophosphamide in breast cancer, sponsored by Istituto Nazionale Tumori IRCCS Fondazione Pascale. Primary endpoint: Pathologic complete response rate. Started Jun 2007; status: terminated.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2006-003993-85.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-003993-85.